WO2001007025A3 - Traitement des anomalies cardiaques au moyen d'aryloxy-propanolamines - Google Patents

Traitement des anomalies cardiaques au moyen d'aryloxy-propanolamines Download PDF

Info

Publication number
WO2001007025A3
WO2001007025A3 PCT/US2000/016320 US0016320W WO0107025A3 WO 2001007025 A3 WO2001007025 A3 WO 2001007025A3 US 0016320 W US0016320 W US 0016320W WO 0107025 A3 WO0107025 A3 WO 0107025A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
cardiac abnormalities
propanolamines
aryloxy
aryloxy propanolamines
Prior art date
Application number
PCT/US2000/016320
Other languages
English (en)
Other versions
WO2001007025A2 (fr
Inventor
William Elmer Bloomquist
Marlene Lois Cohen
Original Assignee
Lilly Co Eli
William Elmer Bloomquist
Marlene Lois Cohen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, William Elmer Bloomquist, Marlene Lois Cohen filed Critical Lilly Co Eli
Priority to AU60495/00A priority Critical patent/AU6049500A/en
Publication of WO2001007025A2 publication Critical patent/WO2001007025A2/fr
Publication of WO2001007025A3 publication Critical patent/WO2001007025A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une méthode permettant de traiter les dysfonctionnements et anomalies cardiaques au moyen d'aryloxy-propanolamines chez un sujet nécessitant un tel traitement. La méthode consiste à administrer au sujet une dose efficace d'un composé de formule (I) ou (VIII).
PCT/US2000/016320 1999-07-22 2000-07-11 Traitement des anomalies cardiaques au moyen d'aryloxy-propanolamines WO2001007025A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60495/00A AU6049500A (en) 1999-07-22 2000-07-11 Treatment of cardiac abnormalities with aryloxy propanolamines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14517499P 1999-07-22 1999-07-22
US60/145,174 1999-07-22

Publications (2)

Publication Number Publication Date
WO2001007025A2 WO2001007025A2 (fr) 2001-02-01
WO2001007025A3 true WO2001007025A3 (fr) 2002-01-17

Family

ID=22511930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/016320 WO2001007025A2 (fr) 1999-07-22 2000-07-11 Traitement des anomalies cardiaques au moyen d'aryloxy-propanolamines

Country Status (2)

Country Link
AU (1) AU6049500A (fr)
WO (1) WO2001007025A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007026A2 (fr) * 1999-07-22 2001-02-01 Eli Lilly And Company Methode de traitement amelioree du diabete de type ii et de l'obesite
US20080249176A1 (en) * 2004-04-23 2008-10-09 Rasmussen Helge H Methods and Compositions for the Treatment of Myocardial Conditions
EP1947103A1 (fr) * 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, procédés de préparation correspondant et utilisation d'aryloxypropanolamines en tant que médicaments

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611003A1 (fr) * 1993-02-09 1994-08-17 Merck & Co. Inc. Phénylsulfonamides substitués comme B3-agonistes selectives pour le traitement du diabète et de l'obésité
EP0764640A1 (fr) * 1995-09-21 1997-03-26 Eli Lilly And Company Agonistes adrénergiques bêta-3 spécifiques
EP0827746A1 (fr) * 1996-09-05 1998-03-11 Eli Lilly And Company Analogues de carbazole étant agonistes B3-adrénergiques sélectifs
WO1999029672A1 (fr) * 1997-12-05 1999-06-17 Eli Lilly And Company AGONISTES β3-ADRENERGIQUES SPECIFIQUES
WO2001007026A2 (fr) * 1999-07-22 2001-02-01 Eli Lilly And Company Methode de traitement amelioree du diabete de type ii et de l'obesite

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611003A1 (fr) * 1993-02-09 1994-08-17 Merck & Co. Inc. Phénylsulfonamides substitués comme B3-agonistes selectives pour le traitement du diabète et de l'obésité
EP0764640A1 (fr) * 1995-09-21 1997-03-26 Eli Lilly And Company Agonistes adrénergiques bêta-3 spécifiques
US5786356A (en) * 1995-09-21 1998-07-28 Eli Lilly And Company Selective β3 adrenergic agonists
EP0827746A1 (fr) * 1996-09-05 1998-03-11 Eli Lilly And Company Analogues de carbazole étant agonistes B3-adrénergiques sélectifs
WO1999029672A1 (fr) * 1997-12-05 1999-06-17 Eli Lilly And Company AGONISTES β3-ADRENERGIQUES SPECIFIQUES
WO2001007026A2 (fr) * 1999-07-22 2001-02-01 Eli Lilly And Company Methode de traitement amelioree du diabete de type ii et de l'obesite

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANDELORE, MARI RIOS ET AL: "Potent and selective human.beta.3-adrenergic receptor antagonists", J. PHARMACOL. EXP. THER. (1999), 290(2), 649-655, 1999, XP001031847 *
COHEN M L ET AL: "ARYL PROPANOLAMINES: COMPARISON OF ACTIVITY AT HUMAN BETA3 RECEPTORS, RAT BETA3 RECEPTORS AND RAT ATRIAL RECEPTORS MEDIATING TACHYCARDIA", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 126, no. 4, 1999, pages 1018 - 1024, XP001015387, ISSN: 0007-1188 *
WEBER A E ET AL: "3-pyridyloxypropanolamine agonists of the beta3 adrenergic receptor with improved pharmacokinetic properties", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 16, 18 August 1998 (1998-08-18), pages 2111 - 2116, XP004137229, ISSN: 0960-894X *
WEBER A E ET AL: "Potent, selective benzenesulfonamide agonists of the human beta3 adrenergic receptor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 9, 1 May 1998 (1998-05-01), pages 1101 - 1106, XP004137028, ISSN: 0960-894X *

Also Published As

Publication number Publication date
AU6049500A (en) 2001-02-13
WO2001007025A2 (fr) 2001-02-01

Similar Documents

Publication Publication Date Title
AU5032500A (en) Treatment of irregular ventricular contractions
HK1023064A1 (en) Method of inhibiting bacterial or fungal growth using a complexing agent
WO2002053101A3 (fr) Procede de traitement de troubles fibrogenes et autres symptomes de type ivc
CA2140106A1 (fr) Methode de traitement des affections vasculaires hyperproliferatives
AU3920900A (en) Compounds and methods to treat cardiac failure and other disorders
AU2002218742A1 (en) Application of photochemotherapy for the treatment of cardiac arrhythmias
AU2001249881A1 (en) Method of treating the heart
EP1266658A3 (fr) Utilisation de dérivés de l'acide bétulinique pour le traitement et la prévention du mélanome
WO2001064676A3 (fr) INHIBITEURS DE LA P38-α KINASE
WO2000059487A3 (fr) Utilisation de flupirtine pour le traitement de la fibromyalgie et d'affections associees a la fibromyalgie
EP1126855A4 (fr) Methodes pour la prevention/le traitement des cellules auditives ciliees et neurones cochleaires endommages
WO2001058891A3 (fr) Derives de piperazine et de piperidine
PL310476A1 (en) Application of lamotrigin in treating neuro-aids diseases
CA2388939A1 (fr) Traitements therapeutiques pour des deficiences en cellules sanguines
SE0104248D0 (sv) Method of treatment
CA2383785A1 (fr) Techniques d'utilisation d'inhibiteurs selectifs de recaptage de serotonine a apparition rapide pour traiter un dysfonctionnement sexuel
CA2134347A1 (fr) Derives du thiazole ou de l'imidazole utilises comme inhibiteurs de la reaction de maillard
AU4385399A (en) Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer
WO2001007026A3 (fr) Methode de traitement amelioree du diabete de type ii et de l'obesite
WO2001010427A3 (fr) Utilisation topique d'agents anti-muscarinique
WO2002096362A3 (fr) Methode de traitement de maladies fibreuses ou d'autres indications
MY133785A (en) Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias
WO2001007025A3 (fr) Traitement des anomalies cardiaques au moyen d'aryloxy-propanolamines
WO2000006185A3 (fr) Procedes d'utilisation d'un analogue de somatostatine
WO1999065475A3 (fr) Combinaison de phentolamine et apomorphine pour le traitement concernant les fonctions et les dysfonctionnements sexuels

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP